The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
ICICI Direct’s analysis of Cipla’s Q3FY22 results
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Subscribe To Our Newsletter & Stay Updated
